These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 37522622

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study.
    Su Z, Zhang C, Gao C, Li C, Li R, Zheng Z.
    Arthritis Res Ther; 2024 Sep 18; 26(1):163. PubMed ID: 39294688
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus.
    Miyazaki Y, Nakayamada S, Sonomoto K, Kawabe A, Inoue Y, Okubo N, Iwata S, Hanami K, Tanaka Y.
    Rheumatology (Oxford); 2022 Aug 30; 61(9):3614-3626. PubMed ID: 34962998
    [Abstract] [Full Text] [Related]

  • 5. Belimumab in early systemic lupus erythematosus: A propensity score matching analysis.
    Lu C, He N, Dou L, Yu H, Li M, Leng X, Zeng X.
    Immun Inflamm Dis; 2024 Aug 30; 12(8):e1362. PubMed ID: 39172013
    [Abstract] [Full Text] [Related]

  • 6. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.
    Touma Z, Sayani A, Pineau CA, Fortin I, Matsos M, Ecker GA, Chow A, Iczkovitz S.
    Rheumatol Int; 2017 Jun 30; 37(6):865-873. PubMed ID: 28280970
    [Abstract] [Full Text] [Related]

  • 7. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L, Tincani A, Urban ML, Emmi G, Ceccarelli F, Conti F, Bortoluzzi A, Govoni M, Tani C, Mosca M, Ubiali T, Gerosa M, Bozzolo E, Canti V, Cardinaletti P, Gabrielli A, Tanti G, Gremese E, De Marchi G, De Vita S, Fasano S, Ciccia F, Pazzola G, Salvarani C, Negrini S, Puppo F, Di Matteo A, De Angelis R, Orsolini G, Rossini M, Faggioli P, Laria A, Piga M, Mathieu A, Scarpato S, Rossi FW, de Paulis A, Brunetta E, Ceribelli A, Selmi C, Prete M, Racanelli V, Vacca A, Bartoloni E, Gerli R, Larosa M, Iaccarino L, Doria A.
    Arthritis Rheumatol; 2020 Aug 30; 72(8):1314-1324. PubMed ID: 32275125
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Belimumab for systemic lupus erythematosus.
    Singh JA, Shah NP, Mudano AS.
    Cochrane Database Syst Rev; 2021 Feb 25; 2(2):CD010668. PubMed ID: 33631841
    [Abstract] [Full Text] [Related]

  • 10. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, Tsalapaki C, Pantazi L, Konsta S, Mavragani CP, Dimopoulou D, Ntali S, Katsikas G, Boki KA, Vassilopoulos D, Konstantopoulou P, Liossis SN, Elezoglou A, Tektonidou M, Sidiropoulos P, Erden A, Sfikakis PP, Bertsias G, Boumpas DT.
    Semin Arthritis Rheum; 2018 Dec 25; 48(3):467-474. PubMed ID: 29555348
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from a multicentre study.
    Wang L, Liang X, Cao Z, Wang D, Luo Y, Feng Y, Luo C, Zhi S, Huang Y, Fan Z, Wang C, Liu H, Liu J, Zhang T, Cheng Q, Xie X, Shuai L, Rong Z, Zeng P, Yu H, Lu M, Sun L, Yang S, Zhao D, Zhang W, Wu X, Li Q, Wang Y, Zhang Q, Yang J, Li X, Song H, Tang X.
    Rheumatology (Oxford); 2024 May 02; 63(5):1437-1446. PubMed ID: 37606970
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.
    Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Struemper H, Roth D.
    Mod Rheumatol; 2019 May 02; 29(3):452-460. PubMed ID: 29792370
    [Abstract] [Full Text] [Related]

  • 18. Impact of subcutaneous belimumab on disease activity, patient satisfaction, and metabolic profile in long-lasting systemic lupus erythematosus.
    Yamato M, Shirai T, Ishii Y, Sato H, Ishii T, Fujii H.
    Clin Rheumatol; 2024 Mar 02; 43(3):1023-1035. PubMed ID: 38334937
    [Abstract] [Full Text] [Related]

  • 19. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.
    Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Petri M, Fettiplace J, Roth DA, Ji B, Heath A.
    Arthritis Rheumatol; 2019 Jul 02; 71(7):1125-1134. PubMed ID: 30771238
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.